KIT and hematopoietic and lymphoid system neoplasm: Caution also must be taken in applying these studies to more aggressive disease variants where expansion of other cell types, such as occurs in mastocytosis with as associated hematologic neoplasm, will lead to mixed sources of EVs, and/or where treatment with more aggressive therapies such as steroids, 2-CDA, alpha interferon, and KIT inhibitors may well alter the number, composition, and biologic effects of EVs.